EDGAR·FLOW

Allarity Therapeutics, Inc. — Form 8-K

Filed November 19, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 48/100
What the filing says
The U.S. Patent and Trademark Office granted U.S. Patent No. 12,806,205 covering stenoparib treatment regimens with 36 allowed claims protecting twice-daily oral dosing for advanced ovarian cancer and other solid tumors (breast, colon, pancreatic, prostate), with patent protection extending to 2045. The patent covers the dosing strategy Allarity intends to advance in its ongoing Phase 2 TARPON clinical program and complements a previously issued patent for stenoparib's companion diagnostic (Drug Response Predictor).
Why this rating

Patent protection to 2045 is valuable for a clinical-stage biotech but patent strength alone does not de-risk clinical/regulatory execution; firm at $14.7M market cap with no revenue depends entirely on stenoparib success.

View original filing on SEC.gov ↗ ALLR · stock on Yahoo Finance ↗

See more from November 19, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.